Lubiprostone

芦比前列酮

Report date: 2026/02/26 20:00:22
NMEFirst In Class

Base Information

Drug NameLubiprostone
Drug Alias Name鲁比前列素lubiprostona芦比前列酮Lubiprostonum鲁比前列酮 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionChloride channel protein 2 agonists
TargetsChloride channel protein 2
Therapy Area/IndicationsChronic idiopathic constipationDrug-Related Side Effects and Adverse ReactionsOpioid-Induced Constipation +[9] 
Global Approved IndicationsChronic idiopathic constipationOpioid-Induced ConstipationConstipation
Approved Indications in ChinaConstipation
Original Approved Country/TerritoryUnited States
Original Approved Date2006/01/31
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSucampoMallinckrodt Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSucampo Pharma Americas LlcMylan NvAlexandria University +[7] 
Inactive CompaniesAugusta UniversityArmy Medical University, ChinaSucampo Pharmaceuticals Inc +[12] 
Active IndicationsChronic idiopathic constipationDrug-Related Side Effects and Adverse ReactionsOpioid-Induced Constipation +[8] 
Inactive IndicationsIrritable Bowel Syndrome

Other Information

ATC CodeA06AX03
Related LinksWikipediaDrugBankKEGG